Search the Newsreel

CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder

CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026

CAMP4 Therapeutics will host a virtual Analyst Day on September 28, 2026, to discuss CMP-002, a potential disease-modifying therapy for SYNGAP1-related disorder. The event will feature presentations from executive leadership, patient advocates, and a leading KOL, covering the unmet clinical need, trial design for …

CAMP Q2 2026 Earnings: Narrow EPS Miss Leaves Shares Flat as Pre-Commercial Investment Continues - Profit Cycle Analysis

Camp4 CFO Kelly Gold buys $39,600 in company stock

Camp4 Therapeutics CFO Kelly Gold purchased 10,000 shares of company stock for $39,600, despite the stock's recent decline of 8% but overall yearly gain of 170%. This transaction coincides with positive analyst upgrades and new coverage for Camp4, and Gold's appointment to X4 Pharmaceuticals' …

CAMP4 to Participate in Upcoming Investor Conferences

Camp4 Therapeutics director Andrew Schwab sells $1.6m in stock

Camp4 Therapeutics director Andrew J. Schwab sold 400,000 shares of common stock for $1.616 million on August 27, 2026. This sale occurred despite the company's stock being up 161% over the past year, though it declined 11% in the week prior. The company, which …

CAMP4 (CAMP) Earnings Snapshot: The EPS Result Is Below Expectation for the Current Session; Price Reaction: The Stock Gains 0.45% on the Day - Dividend Cut Risk

CAMP Technical Analysis & ETF Price Forecast

This article provides a technical analysis and price forecast for CAMP4 Therapeutics Corp (CAMP). It presents various technical indicators, including moving averages, RSI, MACD, and support/resistance levels. The overall technical sentiment for CAMP is currently rated as Neutral, despite several moving average indicators suggesting …

Camp4 Therapeutics Insider Sold Shares Worth $879,719, According to a Recent SEC Filing

Balyasny Asset Management L.P. Reduces Stake in Camp4 Therapeuti

Balyasny Asset Management L.P. has reduced its stake in Camp4 Therapeutics Corp (CAMP) by 1.57%, selling 41,340 shares at $4.37 each. Despite the reduction, Balyasny still holds a 4.99% stake in Camp4, indicating a cautious but continued interest in the biopharmaceutical company. Camp4 Therapeutics …

Camp4 Therapeutics CSO Daniel Tardiff sells $8,272 in common stock

Daniel Tardiff, CSO of Camp4 Therapeutics, sold 1,738 shares of company stock for $8,272 on August 19, 2026. This transaction follows a 202% return for Camp4 shares over the past year, though the stock is near its Fair Value estimate according to InvestingPro. The …

Camp4 Therapeutics CSO Daniel Tardiff sells $8,272 in common stock By Investing.com

Daniel Tardiff, Chief Scientific Officer at Camp4 Therapeutics (NASDAQ:CAMP), sold 1,738 shares of the company's common stock for a total of $8,272. These shares were acquired through an employee stock purchase plan and sold at $4.76 per share. The transaction follows a 202% return …

Camp4 Therapeutics (NASDAQ: CAMP) backer sees stake diluted after new share sales

Polaris-affiliated funds and individuals have filed an amended Schedule 13D/A for Camp4 Therapeutics (NASDAQ: CAMP), indicating a diluted ownership stake. This reduction is due to Camp4's sales of additional common shares, decreasing the reporting persons' aggregate percentage ownership by over 1% since the previous …

Camp4 Therapeutics (NASDAQ: CAMP) insider to sell 1,738 shares

An affiliate of Camp4 Therapeutics (NASDAQ: CAMP), Daniel Tardiff, plans to sell 1,738 shares of common stock through J.P. Morgan Securities LLC. The proposed sale is valued at approximately $8,275.55 with an anticipated sale date of August 19, 2026. This notice, filed as a …

CAMP4 Therapeutics (CAMP) Q1 2026 Earnings: Wider-than-Expected Loss Weighs on Shares - Dividend Earnings Report

CAMP4 Therapeutics (CAMP) Q1 2026 Earnings: Wider-than-Expected Loss Weighs on Shares - Earnings Miss Streak

Calamp Corp. (CAMP) News, Articles, Events & Latest Updates

This article provides recent news and updates for Calamp Corp. (CAMP), primarily focusing on CAMP4 Therapeutics Corporation's financial results, team expansion, and stock performance. It highlights earnings and revenue reports, changes in short interest, and an analyst upgrade to "Strong-Buy."

Analysts’ Top NA Picks: CAMP4 Therapeutics Corporation (CAMP), Wayfair (W)

CAMP Q1 2026 Earnings: EPS Miss Widens 49.4% Yet Shares Rally 11.1% on Pipeline Focus - Estimate Revision Count

CAMP4 Therapeutics (CAMP) Jumps 8% to $4.86: Key Levels to Watch - Momentum Stock Picks

Balyasny group discloses 4.99% Camp4 Therapeutics (CAMP) position with warrant blocker

Balyasny Asset Management and its related entities have disclosed a beneficial ownership of approximately 4.99% in Camp4 Therapeutics Corp. (CAMP). This stake, totaling 2,591,097 shares, includes common stock and shares issuable upon warrant exercise, which are subject to a 4.99% Beneficial Ownership Limitation to …

CAMP4 Therapeutics Corporation (CAMP) Reports Q2 Loss, Tops Revenue Estimates

CAMP4 Therapeutics Corporation (CAMP) reported a Q2 loss of $0.22 per share, outperforming the Zacks Consensus Estimate of a $0.24 loss. The company's revenues for the quarter ended June 2026 reached $1.78 million, surpassing estimates by 31.78%. Despite beating earnings and revenue expectations, CAMP …

CAMP4 Q2 Loss Widens to $33.5M; EPS Misses Estimates

CAMP4 Therapeutics reported a Q2 net loss of $33.5 million, significantly wider than the previous year, primarily due to a $20.9 million non-cash derivative loss, causing EPS of $(0.58) to miss estimates. Despite missing revenue consensus, the company's revenue rose 18.8% year-over-year. Post-quarter, CAMP4 …

CAMP4 Therapeutics (Nasdaq: CAMP) widens loss as derivative liability surges

CAMP4 Therapeutics reported a widened net loss of $51.86 million for the six months ended June 30, 2026, primarily due to a $27.12 million non-cash charge from the remeasurement of a derivative tranche liability. Despite the loss, the company extended its cash runway through …

CAMP4 Therapeutics (CAMP) widens Q2 2026 loss, boosts cash runway to 2028

CAMP4 Therapeutics reported a wider net loss of $33.5 million in Q2 2026, primarily due to a non-cash loss from a derivative liability. Despite this, the company's research and collaboration revenue increased, and it successfully extended its cash runway through the end of 2028 …

CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights

CAMP4 Therapeutics announced its Q2 2026 financial results and corporate highlights, including securing regulatory clearance in Australia and Argentina for its Phase 1/2 clinical trial of CMP-002 for SYNGAP-1 related disorder, with trial initiation expected in Q4 2026. The company also raised an additional …

Camp4 Therapeutics Corp SEC Filing (Aug 13, 2026)

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Given Average Recommendation of "Moderate Buy" by Analysts

Analysts have given CAMP4 Therapeutics Corporation (NASDAQ:CAMP) an average recommendation of "Moderate Buy," with seven analysts recommending a buy and two a sell. The average 12-month price target is $8.36, significantly higher than the current share price of $4.22. Recent actions include an upgrade …

Trails Edge reports 6% Camp4 Therapeutics stake (CAMP) totaling 3.79M shares

Trails Edge Capital Partners, Trails Edge Biotechnology Master Fund, and Ortav Yehudai have reported a beneficial ownership of 3,790,636 shares of Camp4 Therapeutics Corp (CAMP) common stock, representing 6% of the outstanding shares as of August 3, 2026. Trails Edge Biotechnology directly holds these …

CAMP Q1 2026 Earnings: EPS Miss Deepens 49.4% as Pre-Revenue Biotech Navigates Pipeline Progress - Earnings Surprise Stocks

Yuri Maricich Acquires 6,551 Shares of CAMP4 Therapeutics (NASDAQ:CAMP) Stock

Yuri Maricich, an insider at CAMP4 Therapeutics (NASDAQ:CAMP), recently acquired 6,551 shares at $1.65 each, increasing their total holdings by over 108% to 12,611 shares. This comes as the company's stock has fallen, and it reported a quarterly loss that missed analyst estimates. Despite …

Richard Young Buys 16,378 Shares of CAMP4 Therapeutics (NASDAQ:CAMP) Stock

Richard Young, a director at CAMP4 Therapeutics (NASDAQ:CAMP), recently purchased 16,378 shares at $1.65 each, increasing his total holdings by 9.63% to 186,388 shares. Despite this insider buying, the stock fell 3.6% to $4.01 after the company reported a larger-than-expected quarterly loss of $0.32 …

CAMP4 Therapeutics (NASDAQ:CAMP) CEO Josh Mandel-Brehm Purchases 6,551 Shares